by Daniel Schwartz | Nov 24, 2022 | Clinical Trials
CLINICAL TRIALS 7 ways the EMPA-KIDNEY trial will impact clinical care in CKD EMPA-KIDNEY was a clinical trial testing whether taking a single pill of empagliflozin every day prevents worsening of kidney disease or deaths from heart disease in people who have chronic...
by Daniel Schwartz | Jun 17, 2017 | Clinical Trials
CLINICAL TRIALS Personalized decision support and the move from NNT to iNNT The SPRINT trial made waves in the field of hypertension, showing evidence for reduced hard clinical endpoints (a combined outcome of myocardial infarction, acute coronary syndrome not...
by Daniel Schwartz | Nov 15, 2015 | Clinical Trials
CLINICAL TRIALS Will SPRINT Change Our Systolic BP Target in Hypertensive Patients from 140 to 120 mm Hg? At last week’s Medicine rounds at the Royal Columbia Hospital, I presented the results from the recently published SPRINT trial. SPRINT Research Group, Wright JT...
by Daniel Schwartz | Aug 19, 2015 | Health Policy
HEALTH POLICY Temporary Visitor Visas for Donating a KidneY This is a highly subjective list, but these trials have been included as they have had a meaningful impact on guidelines, patients and clinicians at a global scale. As a resident in the newly created...
Recent Comments